More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes
To the Editor: Ludvigsson et al. (Feb. 16 issue) 1 report the results of the DIAGNODE-1 (GAD-Alum [Diamyd] Administered into Lymph Nodes in Combination with Vitamin D in Type 1 Diabetes) trial. They found that injection of alum-formulated glutamic acid decarboxylase (GAD-alum) into the inguinal lymph node plus administration of oral vitamin D was "associated with preservation of residual beta-cell function" and changes to immunologic markers in patients with type 1 diabetes. Although the authors introduce an interesting new approach, their data, as presented, do not support their conclusions adequately. In brief, the authors do not provide statistical data to support assertions regarding the stable C-peptide level in the patients. They also do not provide raw data to support their accounts of changes in immunologic markers, and they do not adequately discuss how the "historical agematched patients" from specific trials 2-4 were chosen as a comparison group. Finally, they do not show the standard-error bars that are necessary to understand this small descriptive data set (see Fig. 1 of their article, available at NEJM.org). Conclusive statements based on the results of small pilot studies are inherently tenuous, but they are particularly problematic when inadequate information is provided to support the findings. 
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The authors and a colleague reply: Several years may be required to conduct well-powered, randomized, placebo-controlled trials with long follow-up in patients with type 1 diabetes. Thus, although conclusive statements based on pilot studies are inherently tenuous, small pilot trials, even without controls, can speed up the process and are needed to test new approaches before the initiation of full-scale, randomized, controlled trials.
In this early trial, autoantigen was injected into each patient's lymph nodes after ethics approval and written informed consent were obtained. There are data from only six patients, and standard errors are now shown in the corrected Figure 1 ; inherently, such data do not have strong statistical power. In addition, the placebo group in our original Figure 1D should have been labeled as the TrialNet 1 placebo group, not the DIAGNODE-1 placebo group. This error has been corrected.
Our open-label trial had no controls, but when we compare the results regarding C-peptide levels with data from other trials 2,3 and with a control group from a GAD-alum trial in which autoantigen was administered subcutaneously in patients of a similar age, 1 the results appear to be promising (Fig. 1D) . Additional data in Figure  1E show in vitro type 2 helper T-cell cytokine secretion that is more pronounced than that observed after subcutaneous administration of higher doses of GAD-alum. 4 Furthermore, although most cytokine levels decreased to very 
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correction Intralymphatic Injection of Autoantigen in Type 1 Diabetes (February 16, 2017; 376:697-9) . In the lower portion of Figure  1D (page 698), "DIAGNODE-1" should have been "TrialNet." The article is correct at NEJM.org.
notices
Notices submitted for publication should contain a mailing address and telephone number of a contact person or department. We regret that we are unable to publish all notices received.
UPDATE IN INTERNAL MEDICINE 2017
The course will be offered in Boston, Dec. 3-9. It is joitly presented by Harvard Medical School and Beth Israel Deaconess Medical Center.
Contact the Department of Continuing Education, Harvard Medical School, P.O. Box 825, Boston, MA 02117-0825; or call 617-384-8600; or e-mail ceprograms@hms.harvard.edu; or see http://www.updateinternalmedicine.com.
26TH WORLD CONGRESS OF LYMPHOLOGY
The biennial congress of the International Society of Lymphology will be held in Barcelona, Contact the Congress Secretariat, Arantxa Events, Urban Business Center, Urgell 143, 2°, despacho A, 08036 Barcelona, Spain; or call (34) 935565505; or e-mail info@lymphologycongress2017 .com; or see http://www.lymphologycongress2017.com. Copyright © 2017 Massachusetts Medical Society. All rights reserved.
